Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

How 11 Big Pharma companies are using AI

By Brian Buntz | June 15, 2023

pharma R&D

[metamorworks/Adobe Stock]

Pharma companies are ramping up their reliance on AI in drug discovery, clinical trials and manufacturing. Bloomberg recently frame the technology as providing a $50 billion opportunity to the sector. GlobalData noted that the pandemic played a role in stoking interest in AI. But given the hype often surrounding the technology, it can be difficult to gauge actual impacts and outcomes of such initiatives, which largely  remain undisclosed.

The pharma industry faces mounting pressures to discover and develop new drugs faster and at lower costs. AI has emerged as a promising tool to help overcome long-standing challenges like high failure rates, lengthy development timelines, and resource inefficiency.

While pharma companies are making big bets on AI, the actual impacts and outcomes of many initiatives remain largely behind the scenes. Still, there are some examples that provide a glimpse into how AI may be shaping the future of drug development and healthcare. Below, discover how 11 Big Pharma companies are using AI to transform the landscape of drug discovery, clinical trials and manufacturing.

    1. Sanofi partnered with Aily Labs to develop an AI platform called “plai” in 2018, with the goal of using AI for drug discovery, clinical trials and manufacturing. lai aggregates Sanofi’s internal data to support decision making across the drug development process. Sanofi has also partnered with Hillo to adapt its AI technology for connected insulin pens, demonstrating the company’s interest in using AI for both drug development and connected healthcare products.

    2. Pfizer has used IBM’s supercomputing and AI since 2020 to develop new drugs like PAXLOVID, an oral COVID-19 treatment approved in 2022. They claim this reduced computational time by 80-90%, stating that the technology helped the team design the drug in four months. The Big Pharma has also inked a deal with CytoReason, which has created an AI model of the immune system.

    3. Novartis is employing AI to improve drug discovery and boost efficiency. The firm has more than 150 ongoing projects applying AI across the business. Novartis partnered with Microsoft and NVIDIA, and aims to scale AI over a decade to improve access, costs, and health outcomes, though outcomes so far are unclear.

    4. Janssen is exploring AI for drug discovery, clinical trials, diagnosing diseases and manufacturing, as sister site Drug Discovery & Development noted. Its Trials360.ai service optimizes trial design, improving care and outcomes. With more than 100 AI projects, Janssen is adopting a scalable approach to test and deploy AI.

    5. AstraZeneca partnered with Oncoshot in 2021 to match patients to trials using AI and BenevolentAI to identify targets, though the timescale and outcomes of these partnerships are unknown. The latter partnership has proven successful with AstraZeneca selecting five targets to enter its portfolio. Two are in chronic kidney disease (CKD) and three in idiopathic pulmonary fibrosis (IPF). Since then, the companies have expanded the partnership to systemic lupus erythematosus and heart failure.

    6. Bristol Myers Squibb has partnered with Exscientia to use AI for small molecule drug discovery. The collaboration will use Exscientia’s AI platforms to accelerate the discovery of small molecule drug candidates across multiple disease areas, including oncology and immunology. By combining Exscientia’s AI expertise with BMS’s experience in drug development, the partners aim to speed up the early stages of the drug pipeline.

    7. Bayer has also partnered with Exscientia to explore AI for small molecule drug discovery. Exscientia will collaborate with Bayer on three initial projects focused on cardiovascular disease and oncology targets. Under the agreement, Exscientia may receive up to €240 million in payments, including upfront research funding, clinical milestones, and near-term milestones. The partnership aims to combine Exscientia’s AI platform with Bayer’s expertise in drug development to speed up the discovery of new small molecule drug candidates for some of Bayer’s key disease areas of focus.

    8. Merck partnered with BenchSci, Atomwise, C4 Therapeutics and ACMED on various AI drug discovery and development initiatives.

    9. GSK has partnered with Cloud Pharmaceuticals and Insilico Medicine to utilize their AI platforms for target identification, drug design, and lead generation. GSK also has an Advantage AI program to explore AI partnerships.

    10. Roche partnered with Recursion Pharmaceuticals to use their AI platforms for drug discovery and development. After announcing more than 25 AI partnerships, Roche established an AI hub.

    11. Lilly, a $420 billion Big Pharma, recently told Insider it aims to grow its ‘digital worker-equivalent workforce’ to 2.4 million hours, or 274 years of human work, by year-end through more than 100 AI projects. CEO David Ricks noted that he sees AI augmenting human productivity, automating regulatory processes, and enabling new drug discovery constructs chemists wouldn’t visualize alone. Ricks expects AI to ‘massively change the productivity of the workplace,’ freeing people for more valuable work.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Comments

  1. David Litterello says

    June 20, 2023 at 8:07 pm

    Great article!

    Reply
  2. Marleen Colangelo says

    October 1, 2023 at 9:03 pm

    Thank you for keeping us informed!

    Reply

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE